Celltrion reported Q2 revenue of 1.3 trillion won and operating profit of 430 billion won, exceeding consensus by approximately 5% and 8% respectively. Korea Investment Securities lowered its target price for Celltrion stocks from 276,000 won to 260,000 won, reflecting broader valuation pressure across Korea's bio sector. The KRX Healthcare Index declined from the 5600 level in February to the 3800 level recently.
Celltrion Reports Q2 Revenue of 1.3 Trillion Won
Celltrion recorded consolidated revenue of 1.3 trillion won and operating profit of 430 billion won in Q2, representing year-over-year increases of more than 35% and more than 77% respectively. The operating profit margin reached approximately 33%, a significant improvement from the previous year. The revenue figure exceeded market consensus by about 5%, while operating profit surpassed expectations by about 8%.
Securities analysts attributed the strong performance to expanded sales of new biosimilar products. The increasing proportion of new products such as Remsima SC and Omliklo improved the product mix, with gross profit margin estimated to have risen from the mid-50% range last year to the low-60% range this year. The won-dollar exchange rate increase and operating leverage effects from revenue growth further enhanced profitability.
Korea Investment Securities Lowers Celltrion Target Price to 260,000 Won
Korea Investment Securities adjusted its target price for Celltrion from approximately 276,000 won to 260,000 won. The brokerage explained the downward revision reflected the valuation decline across Korea's bio sector rather than weakness in Celltrion's business performance. The KRX Healthcare Index, which represents the domestic pharmaceutical and biotech sector, exceeded the 5600 level in February but recently fell to the 3800 level, continuing its weak trend. Sector-wide investor sentiment contraction has prevented individual companies' earnings improvements from being fully reflected in stock prices.
IBK Investment Securities assessed that Celltrion's second consecutive quarter of beating company-provided operating profit guidance (following Q1) has heightened expectations for H2 performance. A financial investment industry official stated that while sector-wide investor sentiment contraction poses a short-term burden, Celltrion is simultaneously demonstrating new product expansion and profitability improvement, with the speed of resolving the gap between earnings and corporate value being a key variable for H2 stock price.
Celltrion Plans H2 Product Launches in US and Europe Markets
Celltrion has scheduled Steqima's indication expansion in Europe and US launches of Omliklo and Idenzel for the second half of the year. Korea Investment Securities identified variables for H2 stock price recovery including Zymfentra prescription expansion and changes to the US biosimilar interchangeability system. The company has already established direct sales systems in the US and Europe.
The market environment is becoming more favorable according to analyst assessments. Regulatory easing to expand the biosimilar market continues centered on the US, and patent expirations of global blockbuster biopharmaceuticals are occurring in succession. The biosimilar market is projected to grow significantly over the coming years.
FAQ
What revenue did Celltrion report for Q2?
Celltrion reported Q2 consolidated revenue of 1.3 trillion won and operating profit of 430 billion won, exceeding market consensus by approximately 5% for revenue and 8% for operating profit.
Why did Korea Investment Securities lower Celltrion's target price despite strong earnings?
Korea Investment Securities lowered Celltrion's target price from 276,000 won to 260,000 won to reflect the valuation decline across Korea's entire bio sector, not due to Celltrion-specific performance issues. The KRX Healthcare Index fell from the 5600 level in February to the 3800 level recently.
What product launches does Celltrion have planned for the second half of the year?
Celltrion has scheduled Steqima's indication expansion in Europe and US launches of Omliklo and Idenzel for the second half of the year.
